While single-agent activity has been reported in heavily pre-treated patients with these subtypes, the combination data with letrozole in the first-line treatment of post-menopausal breast cancer has brought the fundamental biology of the cyclin:CDK:RB signaling complex to the forefront of new therapeutic approaches to cancers. Here, RB1 is linked to cancer.